Robert Driscoll
Stock Analyst at Wedbush
(3.07)
# 1,171
Out of 5,172 analysts
171
Total ratings
39.33%
Success rate
1.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Maintains: Outperform | $13 → $14 | $2.11 | +563.51% | 11 | Mar 17, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Outperform | $6 → $11 | $4.45 | +147.19% | 10 | Mar 17, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Outperform | $10 | $5.00 | +100.00% | 8 | Mar 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $34 → $36 | $12.74 | +182.57% | 6 | Mar 11, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Neutral | $30 → $22 | $21.44 | +0.28% | 8 | Mar 9, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $38 → $36 | $8.26 | +335.84% | 12 | Mar 6, 2026 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $15 → $19 | $19.42 | -2.16% | 5 | Mar 6, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Underperform | $7 | $11.82 | -40.78% | 1 | Feb 26, 2026 | |
| ARVN Arvinas | Maintains: Neutral | $9 → $11 | $10.94 | +0.55% | 10 | Feb 25, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $49 → $52 | $32.75 | +58.78% | 10 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $53 | $37.15 | +42.66% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $7 | $0.74 | +843.14% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $6.98 | +172.21% | 8 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $147 | $95.78 | +53.48% | 9 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $65.08 | +7.56% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $8.60 | +341.86% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $10.90 | +147.71% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $2.62 | +52.67% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.79 | +663.36% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $15.63 | +8.77% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $21.64 | +38.63% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $6.92 | +1,056.07% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $14.06 | +426.32% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $5.15 | +55.34% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.46 | +379.45% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.24 | -5.66% | 4 | May 19, 2020 |
Black Diamond Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $2.11
Upside: +563.51%
CytomX Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $6 → $11
Current: $4.45
Upside: +147.19%
Foghorn Therapeutics
Mar 12, 2026
Reiterates: Outperform
Price Target: $10
Current: $5.00
Upside: +100.00%
Cullinan Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $34 → $36
Current: $12.74
Upside: +182.57%
Day One Biopharmaceuticals
Mar 9, 2026
Downgrades: Neutral
Price Target: $30 → $22
Current: $21.44
Upside: +0.28%
Kura Oncology
Mar 6, 2026
Maintains: Outperform
Price Target: $38 → $36
Current: $8.26
Upside: +335.84%
Tango Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $15 → $19
Current: $19.42
Upside: -2.16%
Eikon Therapeutics
Feb 26, 2026
Initiates: Underperform
Price Target: $7
Current: $11.82
Upside: -40.78%
Arvinas
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $10.94
Upside: +0.55%
IDEAYA Biosciences
Feb 18, 2026
Maintains: Outperform
Price Target: $49 → $52
Current: $32.75
Upside: +58.78%
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $37.15
Upside: +42.66%
Feb 10, 2026
Maintains: Outperform
Price Target: $11 → $7
Current: $0.74
Upside: +843.14%
Feb 4, 2026
Maintains: Outperform
Price Target: $18 → $19
Current: $6.98
Upside: +172.21%
Jan 9, 2026
Maintains: Outperform
Price Target: $80 → $147
Current: $95.78
Upside: +53.48%
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $65.08
Upside: +7.56%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $8.60
Upside: +341.86%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $10.90
Upside: +147.71%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.62
Upside: +52.67%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.79
Upside: +663.36%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $15.63
Upside: +8.77%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $21.64
Upside: +38.63%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $6.92
Upside: +1,056.07%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $14.06
Upside: +426.32%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $5.15
Upside: +55.34%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.46
Upside: +379.45%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.24
Upside: -5.66%